University of Cincinnati Cancer Center at ASH 2025

The University of Cincinnati Cancer Center will be at the 67th ASH Annual Meeting and Exposition. Connect with our researchers and physician-scientists December 6-9, 2025.

Visit us in booth #2178

Visit us at booth #2178 to meet our faculty, explore opportunities and learn more about the Cancer Center.

University of Cincinnati Cancer Center Presenters & Moderators

To view more abstract details, visit the  ASH Annual Meeting abstracts site.

Saturday, December 6

Eric Vick, MD
Session Name: 604
Moderating: Molecular Pharmacology and Drug Resistance
Session Time: 4-5 p.m. ET

Mark Rudolph (resident/fellow)
Session Name: 907. Outcomes Research: Plasma Cell Disorders: Poster I
Presentation Time: 5:30-7:30 p.m. ET
Title: A prospective pilot study integrating health care coaching into VA hematologic cancer care: A VA-leukemia & lymphoma society (LLS) collaborative initiative
Publication Number: 2797
Room: OCCC - West Halls B3-B4

Sunday, December 7

Emily Curran, MD
Session Name: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Emerging Treatment Paradigms in ALL
Session Time: 9:30-11 a.m. ET
Room: OCCC - West Halls B3-B4

Courtney Jones, MD
Session Name: 602. Myeloid Oncogenesis: Basic: Targeting the NPM1/KMT2A/Menin axis
Session Time: 9:30-11 a.m. ET
Room: OCCC - West Halls B3-B4

Erin Hertlein, PhD
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Therapy resistance across B-cell maturation - from B-ALL to myeloma
Session Time: 9:30-11 a.m. ET
Room: Orange County Convention Center, W224CDGH 

Zula Omer, MD
Session Name: 642. CLL : Clinical and epidemiological Front-line strategies for CLL
Presenting Time: 9:45 - 10 a.m. ET
Title: 0086 Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial
Moderating Time: 4:30 - 6 p.m. ET
Room: OCCW224ABEF

Tahir Latif, MBBS, MBA, FACP
Translational Presentation:
Session Name: 702. CAR-T Cell Therapies: Basic and Translational: Product biology and Single Cell states shaping CAR-T cell outcomes
Session Time: 10 a.m. ET
Title: CD62L Enrichment Achieves Robust Expansion and Memory Phenotype Post-Infusion in Patients with LBCL Treated with Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate
Authors: Akil Marchant¹, Ben Harris², Lora Zhao², Sahithi Cheemalamarri², Shobha Potluri², Tahir Latif³, Umar Farooq⁴, Sarah M. Larson

Clinical Presentation:
Session Name: 628. Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas
Session Time: 4:45 p.m. ET
Title: Rondecabtagene Autoleucel, an Autologous, Dual-Targeting CD19/CD20 CAR T-Cell Candidate Manufactured from CD62L+ Enriched T Cells, Achieves Durable Responses in Patients with Large B-Cell Lymphoma
Authors: Sarah M. Larson¹, Umar Farooq², Tahir Latif³, Felix Mensah⁴, Bradley D. Hunter⁵, Stefan O. Ciurea⁶, Nebu Koshy⁷, Locke Bryan⁸, Boyu Hu⁹,William Clark¹⁰, Hassaan Yasin¹¹, Yeonhee Kim¹², Greg Kaufman¹², Akil Merchant¹³

Emily Curran, MD
Session Name: 616. Acute Myloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Presentation Time: 6-8 p.m. ET
Title: Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old
Submission ID: abs25-11353
Room: OCCC - West Halls B3-B4

Courtney Jones, MD
Session Name: Special-Interest Sessions: Early Faculty Career Development
Presentation Time: 4:30-6 p.m. ET
Title: Developing a Productive Research Program (How to Set Up a New Laboratory) - Part 1
Room: Hyatt - Regency Ballroom S

Monday, December 8

General Poster Session:
Publication Number: 5067
Abstract Title: A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novelmenin inhibitor, balomenib (ZE63-0302): Interim analysis
Category: 600s - Hematologic Malignancy Review Category: 604A. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
Authors: Amy Burd¹, Brian Ledwith¹, Megan Johnstone², Erin Hertlein², Alexander Khvat¹, Ola Elgamal², Ruben Karapetian³, Kate Dokukina¹, Fraser Pickersgill¹, Peter Schrader¹, Nikolay Savchuk¹, Iain Dukes¹, John Byrd^2
1Eilean Therapeutics, Dover, DE, United States, ²University of Cincinnati, Cincinnati, OH, United States, ³ChemDiv Inc, San Diego, CA, United States

General Poster Session:
Publication Number: 1988
Abstract Title: ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases
Category: 600s - Hematologic Malignancy Review Category: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational
Authors: Shailaja Hegde¹, Alexander Khvat², Ruben Karapetian^2,3, Brian Ledwith⁴, Fraser Pickersgill⁴, Megan Johnstone¹, Eric Vick¹, Emily Curran¹, Iain Dukes⁴, Amy Burd⁴, Nikolay Savchuk⁴, Vladislav Parchincky², Igor Rezekin², Erin Hertlein¹, John Byrd^1
1University of Cincinnati, Cincinnati, OH, United States, ²ChemDiv Inc, San Diego, CA, United States, ³University of Coimbra, Coimbra, Portugal, ⁴Eilean Therapeutics, Dover, DE, United States